{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:31:56Z","timestamp":1769549516857,"version":"3.49.0"},"reference-count":50,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"4","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2005]]},"DOI":"10.2133\/dmpk.20.236","type":"journal-article","created":{"date-parts":[[2005,9,2]],"date-time":"2005-09-02T05:55:39Z","timestamp":1125640539000},"page":"236-243","source":"Crossref","is-referenced-by-count":75,"title":["The Quantitative Prediction of In Vivo Enzyme-Induction Caused by Drug Exposure from In Vitro Information on Human Hepatocytes"],"prefix":"10.2133","volume":"20","author":[{"given":"Motohiro","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.20.236_bb0005","first-page":"387","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.2133\/dmpk.20.236_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-2952(97)00239-6","article-title":"In vitro approaches to predicting drug interactions in vivo","volume":"55","author":"von Moltke","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0015","first-page":"415","article-title":"Comparative analysis of cytochrome CYP3A induction in primary cultures of rat, rabbit, and human hepatocytes","volume":"23","author":"Kocarek","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.20.236_bb0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-2797(97)00071-9","article-title":"Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin","volume":"107","author":"Li","year":"1997","journal-title":"Chem. Biol. Interact."},{"key":"10.2133\/dmpk.20.236_bb0025","first-page":"887","article-title":"The use of human hepatocyte cultures to study the induction of cytochrome P-450","volume":"27","author":"Kostrubsky","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.20.236_bb0030","first-page":"595","article-title":"Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes","volume":"18","author":"Pichard","year":"1990","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.20.236_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0009-2797(97)00073-2","article-title":"Quantitative reverse transcriptase WPCR assay for the measurement of inducton in cultured hepatocytes","volume":"107","author":"Mattes","year":"1997","journal-title":"Chem Biol Interact."},{"key":"10.2133\/dmpk.20.236_bb0040","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1073\/pnas.95.21.12208","article-title":"Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction","volume":"95","author":"Bertilsson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.2133\/dmpk.20.236_bb0045","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.2133\/dmpk.20.236_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/abbi.1999.1351","article-title":"P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR","volume":"369","author":"Waxman","year":"1999","journal-title":"Arch. Biochem. Biophys"},{"key":"10.2133\/dmpk.20.236_bb0055","doi-asserted-by":"crossref","first-page":"15122","DOI":"10.1074\/jbc.M001215200","article-title":"Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands","volume":"275","author":"Moore","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.2133\/dmpk.20.236_bb0060","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.20.236_bb0065","first-page":"384","article-title":"Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture","volume":"269","author":"Curi-Pedrosa","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.20.236_bb0070","first-page":"14","article-title":"Urinary 6b-hydroxycortisol and D-glucaric acid exrection rates are not affected by lansoprazole treatment","volume":"35","author":"Rost","year":"1997","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0075","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0016-5085(91)90719-2","article-title":"Omeprazole treatment dose not affect the metabolism of caffeine","volume":"101","author":"Andersson","year":"1991","journal-title":"Gastroenterology"},{"key":"10.2133\/dmpk.20.236_bb0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","article-title":"Rifampin drastically reduces plasma concentrations and effects of oral midazolam","volume":"59","author":"Backman","year":"1996","journal-title":"Clin Pharmcol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0085","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJM198106113042405","article-title":"Qunidinerifampin interaction","volume":"304","author":"Twum-Barima","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.20.236_bb0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0009-9236(95)90168-X","article-title":"Differentiation of absorption and first pass gut and hepatic metabolism in humans: Studies with cyclosporine","volume":"58","author":"Wu","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0095","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-9236(97)90150-8","article-title":"Tacrolimus oral bioavailability doubles with coad- ministration of ketoconazole","volume":"62","author":"Floren","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0100","first-page":"1121","article-title":"The nifedipinerifampin interaction. Evidence for induction of gut wall metabolism","volume":"24","author":"Holtbecker","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.20.236_bb0105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1067\/mcp.2000.106872","article-title":"Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone","volume":"67","author":"Dilger","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0009-9236(97)90082-5","article-title":"Rifampin reduces plasma concentrations and effects of zolpidem","volume":"62","author":"Villikka","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(97)90176-4","article-title":"Triazolam is ineffective in patients taking rifampin","volume":"61","author":"Villikka","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/009127009903900508","article-title":"Morning spot and 24-hour urinary 6beta-hydroxycortisol to cortisol ratios: interaindividual variability and correlation under basal conditions and conditions of CYP3A4 induction","volume":"39","author":"Tran","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00609878","article-title":"Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzymeinducing capacity of antipyrine, phenobarbitone and rifampicin","volume":"15","author":"Ohnhaus","year":"1979","journal-title":"Europ. J. clin. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0130","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1365-2125.1997.00630.x","article-title":"Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19","volume":"44","author":"Bertilsson","year":"1997","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.2133\/dmpk.20.236_bb0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2125.1985.tb02658.x","article-title":"Verapamil disposition-effects of sulphinpyrazone and cimetidine","volume":"19","author":"Wing","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00003088-199019040-00004","article-title":"Pharmacokinetic drug interactions with cyclosporin (Part I)","volume":"19","author":"Yee","year":"1990","journal-title":"Clin. Pharmacokin."},{"key":"10.2133\/dmpk.20.236_bb0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2125.1987.tb03177.x","article-title":"Cyclosporin-phenytoin interaction: re-evaluation using metabolite data","volume":"24","author":"Rowland","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0773.1998.tb01457.x","article-title":"The effect of dexamethasone on the pharmacokinetics of triazolam","volume":"83","author":"Villikka","year":"1998","journal-title":"Pharmacol. Toxicol."},{"key":"10.2133\/dmpk.20.236_bb0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/j.1552-4604.1998.tb00014.x","article-title":"Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol","volume":"38","author":"Koup","year":"1998","journal-title":"J. Clin. pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0160","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2125.1981.tb01274.x","article-title":"Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects","volume":"12","author":"Perucca","year":"1981","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0165","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2125.1984.tb05028.x","article-title":"Enzyme induction by phenobarbitone and vitamin K1 disposition in man","volume":"18","author":"Park","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0009-9236(97)90148-X","article-title":"The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin","volume":"62","author":"Sarich","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0175","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.1840200516","article-title":"Specific and dose-dependent enzyme induction by omeprazole in human beings","volume":"20","author":"Rost","year":"1994","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.20.236_bb0180","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1994.49","article-title":"Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test","volume":"55","author":"Rost","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0185","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/clpt.1992.126","article-title":"Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin","volume":"52","author":"Rost","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.20.236_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-2797(98)00031-3","article-title":"An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes","volume":"114","author":"Masubuchi","year":"1998","journal-title":"Chem. Biol. Interact."},{"key":"10.2133\/dmpk.20.236_bb0195","first-page":"410","article-title":"Oxidative metabolism of lansoprazole by human liver cytochromes P450","volume":"47","author":"Pichard","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0200","first-page":"673","article-title":"Rifampicin induction of lidocaine metabolism in cultured human hepatocytes","volume":"274","author":"Li","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.20.236_bb0205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/004982500237668","article-title":"Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes","volume":"30","author":"Sahi","year":"2000","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.20.236_bb0210","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0016-5085(90)90963-2","article-title":"Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450","volume":"99","author":"Diaz","year":"1990","journal-title":"Gastroenterology"},{"key":"10.2133\/dmpk.20.236_bb0215","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/abbi.1998.0730","article-title":"Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes","volume":"355","author":"Kostrubsky","year":"1998","journal-title":"Arch. Biochem. Biophysic."},{"key":"10.2133\/dmpk.20.236_bb0220","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0006-2952(95)02175-2","article-title":"Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450","volume":"51","author":"Pichard","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0225","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0006-2952(97)00679-5","article-title":"Effects of chemical inducers on human microsomal epoxide hydrolase in primary hepatocyte cultures","volume":"55","author":"Hassett","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.20.236_bb0230","first-page":"1712","year":"1996"},{"key":"10.2133\/dmpk.20.236_bb0235","first-page":"1630","article-title":"Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach","volume":"277","author":"Izumi","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.20.236_bb0240","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A Pharmacokinetic analysis. program (MULTI) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J. Pharm. Dyn."},{"key":"10.2133\/dmpk.20.236_bb0245","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.2133\/dmpk.20.236_bb0250","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2133\/dmpk.18.365","article-title":"The intestinal first pass metabolism of the substrates for CYP3A4 and P-glycoprotein-Quantitative analysis based on the literature information","volume":"18","author":"Kato","year":"2003","journal-title":"Drug Metabol. Pharmacokin."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715307576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715307576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T11:02:32Z","timestamp":1706526152000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715307576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005]]}},"alternative-id":["S1347436715307576"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.20.236","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2005]]}}}